ArticleDiscover oncology2025
GNPNAT1 acts as a prognostic biomarker associated with immune infiltration in lung adenocarcinoma and promotes the proliferation and invasion of cancer cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preliminary revelation of potential therapeutic targets related to ribosome biogenesis in lung adenocarcinoma based on bioinformatics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLung cancer persists as the foremost cause of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) representing the predominant histological subtype. Although GNPNAT1 has been implicated as a prognostic indicator in breast and prostate malignancies, its functional significance and mechanistic role in LUAD remain to be elucidated.
methodsWe performed comprehensive bioinformatic analyses to compare GNPNAT1 expression levels and prognostic impact in LUAD versus normal pulmonary tissues. Functional enrichment and single-cell transcriptomic analyses were employed to infer GNPNAT1-associated biological pathways. Immune cell infiltration was quantified using established deconvolution algorithms to assess correlations with GNPNAT1 expression. In vitro assays-including Transwell migration/invasion, colony formation, and flow cytometric evaluation of apoptosis and cell-cycle distribution-were conducted following GNPNAT1 knockdown. Western blotting was utilized to measure alterations in cyclins, CDKs, and MAPK/ERK pathway proteins.
resultsGNPNAT1 was significantly upregulated in LUAD specimens compared with non-neoplastic lung tissue (P < 0.001), and elevated expression portended reduced overall survival. Enrichment analyses highlighted GNPNAT1's involvement in cell proliferation and cell-cycle regulation. Correlation studies revealed that GNPNAT1 expression positively associated with Th2 cells, total T helper cells, and γδ T cells, while inversely correlating with Th17 cells, B lymphocytes, and CD8⁺ T cells. Functional suppression of GNPNAT1 markedly impaired LUAD cell proliferation, migration, and invasion in vitro (P < 0.01), induced apoptosis, and provoked G2/M cell-cycle arrest. Furthermore, GNPNAT1 silencing resulted in decreased levels of Cyclin B1, Cyclin D1, CDK1 (P < 0.01), and phosphorylated ERK.
conclusionGNPNAT1 is overexpressed in lung adenocarcinoma and serves as an adverse prognostic biomarker. Its modulation of immune cell infiltration and engagement of the ERK/MAPK signaling cascade underscores its potential as both a prognostic indicator and therapeutic target in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.